During EHA25 Virtual, researchers presented on hematological concepts and the future of diagnosis, treatment, and research. One such presentation discussed results from the InHIBIT-Bleed study, which examined the efficacy…
According to a story from Medscape, the US Food and Drug Administration (FDA) has recently approved a new oral solution as a treatment for symptoms associated with narcolepsy, a rare…
According to a recent article in BioSpace, Biogen and Eisai have launched a new preclinical Phase III trial of BAN2401 to treat pre-clinical Alzheimer's disease. The new study follows…
As reported in Parkinson's News Today, an investigational therapy to treat patients with Alzheimer's disease and Parkinson’s disease has had its Phase 2 trial approved by the central institutional review…
Recently, pharmaceutical company RIBOMIC announced that the first patient was dosed in their Phase 1 clinical trial. Ultimately, the trial is meant to determine whether RBM-007 could be an effective…
At the start of 2020, we had no idea what this year would bring: COVID-19, a novel coronavirus declared a pandemic in March. As of the morning of July 17,…
This past week, biopharmaceutical company Kiniksa Pharmaceuticals announced that their drug, rilonacept, received Orphan Drug Designation from the FDA. Following positive data from the RHAPSODY Phase 3 clinical trial,…
According to a story from Physician's Weekly, while measuring the concentration of albumin (albuminuria) is widely considered the standard method for staging and screening for chronic kidney disease, a different…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
